Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
CA-19-9 Antigen
Carbohydrates
Carcinoma, Pancreatic Ductal
/ diagnostic imaging
Cross-Sectional Studies
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Genetic Predisposition to Disease
Glypicans
/ genetics
Humans
Pancreatic Neoplasms
/ diagnostic imaging
Prospective Studies
Pancreatic Neoplasms
Circulating exosomes
Endoscopic ultrasound
Genetic predisposition
Glypican-1
Pancreatic cancer precursor lesions
Pancreatic cancer risk groups
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Aug 2022
21 Aug 2022
Historique:
received:
17
02
2022
revised:
30
04
2022
accepted:
24
06
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
Individuals within specific risk groups for pancreatic ductal adenocarcinoma (PDAC) [mucinous cystic lesions (MCLs), hereditary risk (HR), and new-late onset diabetes mellitus (NLOD)] represent an opportunity for early cancer detection. Endoscopic ultrasound (EUS) is a premium image modality for PDAC screening and precursor lesion characterization. While no specific biomarker is currently clinically available for this purpose, glypican-1 (GPC1) is overexpressed in the circulating exosomes (crExos) of patients with PDAC compared with healthy subjects or those harboring benign pancreatic diseases. To evaluate the capacity of GPC1 This cross-sectional study with a prospective unicentric cohort included 88 subjects: 40 patients with MCL, 20 individuals with HR, and 20 patients with NLOD. A control group (CG) was submitted to EUS for other reasons than pancreatic pathology, with normal pancreas and absence of hereditary risk factors ( Half of MCLs harbored worrisome features (WF) or high-risk stigmata (HRS). Pancreatic abnormalities were detected by EUS in 10.0% and 35.0% in HR and NLOD individuals, respectively, all considered non-malignant and "harmless." Median levels of GPC1 GPC1
Sections du résumé
BACKGROUND
BACKGROUND
Individuals within specific risk groups for pancreatic ductal adenocarcinoma (PDAC) [mucinous cystic lesions (MCLs), hereditary risk (HR), and new-late onset diabetes mellitus (NLOD)] represent an opportunity for early cancer detection. Endoscopic ultrasound (EUS) is a premium image modality for PDAC screening and precursor lesion characterization. While no specific biomarker is currently clinically available for this purpose, glypican-1 (GPC1) is overexpressed in the circulating exosomes (crExos) of patients with PDAC compared with healthy subjects or those harboring benign pancreatic diseases.
AIM
OBJECTIVE
To evaluate the capacity of GPC1
METHODS
METHODS
This cross-sectional study with a prospective unicentric cohort included 88 subjects: 40 patients with MCL, 20 individuals with HR, and 20 patients with NLOD. A control group (CG) was submitted to EUS for other reasons than pancreatic pathology, with normal pancreas and absence of hereditary risk factors (
RESULTS
RESULTS
Half of MCLs harbored worrisome features (WF) or high-risk stigmata (HRS). Pancreatic abnormalities were detected by EUS in 10.0% and 35.0% in HR and NLOD individuals, respectively, all considered non-malignant and "harmless." Median levels of GPC1
CONCLUSION
CONCLUSIONS
GPC1
Identifiants
pubmed: 36159010
doi: 10.3748/wjg.v28.i31.4310
pmc: PMC9453765
doi:
Substances chimiques
CA-19-9 Antigen
0
Carbohydrates
0
GPC1 protein, human
0
Glypicans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4310-4327Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Sónia A Melo holds patents in the field of exosomes biology and are licensed to Codiak Biosciences, Inc. All other authors have no conflicts of interest to declare.
Références
Gastroenterology. 2018 Sep;155(3):730-739.e3
pubmed: 29775599
Pancreatology. 2013 Jan-Feb;13(1):48-57
pubmed: 23395570
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31
pubmed: 15551256
Gastroenterology. 2005 Aug;129(2):504-11
pubmed: 16083707
Mol Cancer Res. 2020 Feb;18(2):300-310
pubmed: 31662449
Gastroenterology. 2018 Aug;155(2):490-500.e2
pubmed: 29723506
Oncol Lett. 2018 Jul;16(1):1253-1258
pubmed: 29963198
Oncotarget. 2018 Apr 10;9(27):19006-19013
pubmed: 29721179
Pancreas. 2018 Nov/Dec;47(10):1244-1248
pubmed: 30325864
Oncotarget. 2018 Jun 1;9(42):26900-26933
pubmed: 29928492
Gastroenterology. 2014 Jan;146(1):291-304.e1
pubmed: 24355035
World J Gastroenterol. 2019 Sep 14;25(34):5082-5096
pubmed: 31558858
ACS Nano. 2018 Apr 24;12(4):3311-3320
pubmed: 29570265
Ann Surg. 2014 Apr;259(4):773-80
pubmed: 24253151
Gastrointest Endosc. 2021 Oct;94(4):698-712.e6
pubmed: 33964311
Gastroenterology. 2019 May;156(7):2024-2040
pubmed: 30721664
Cancer Med. 2018 Nov;7(11):5525-5533
pubmed: 30358133
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Gastroenterology. 2020 Jul;159(1):358-362
pubmed: 32416142
Dig Liver Dis. 2022 Jul;54(7):871-877
pubmed: 34840127
Gut. 2022 Jun;71(6):1152-1160
pubmed: 33820756
Gastroenterology. 2012 Apr;142(4):796-804; quiz e14-5
pubmed: 22245846
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Pancreatology. 2017 Sep - Oct;17(5):754-765
pubmed: 28739291
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Dig Liver Dis. 2019 Jan;51(1):4-9
pubmed: 30337098
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710
pubmed: 32135127
J Am Coll Radiol. 2017 Jul;14(7):911-923
pubmed: 28533111
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Gastrointest Endosc. 2018 Jun;87(6):1443-1450
pubmed: 29309780
Am J Gastroenterol. 2018 Apr;113(4):464-479
pubmed: 29485131
World J Gastroenterol. 2014 Jun 28;20(24):7808-18
pubmed: 24976719
Ann Surg. 2016 Dec;264(6):1082-1090
pubmed: 26978570
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Gastroenterology. 2017 Mar;152(4):840-850.e3
pubmed: 27923728
Cancers (Basel). 2019 Jun 19;11(6):
pubmed: 31248203
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
Gastroenterology. 2004 May;126(5):1330-6
pubmed: 15131794
Oncotarget. 2019 Feb 1;10(10):1045-1055
pubmed: 30800217
Gut. 2020 Jan;69(1):7-17
pubmed: 31672839
Pancreatology. 2020 Apr;20(3):571-575
pubmed: 32024605
Gastroenterology. 2008 Apr;134(4):981-7
pubmed: 18395079
Endosc Ultrasound. 2016 Jan-Feb;5(1):8-16
pubmed: 26879161
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi
pubmed: 17996793
Cytojournal. 2014 Jun 02;11(Suppl 1):3
pubmed: 25191517